Key facts
- Bioxodes’s last known valuation is $115.5M (Feb 2025).
- It has raised $39.1M; the latest was Later Stage VC ($82.9M) in Feb 2025.
- Notable investors include European Regional Development Fund (Brandenburg), SambrInvest, Société Fédérale de Participations et d'Investissement, Federal Holding and Investment Company (Brussels), Université Libre de Bruxelles — 12 tracked in total.
- Status: Privately Held (backing).
Investors
12+- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Bioxodes
- ·The full record, as it builds
Funding rounds
No funding rounds for Bioxodes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bioxodes
Operator of a clinical-stage biopharmaceutical company intended to prevent and treat thrombotic and inflammatory diseases. The company's platform prevents blood clot formation without increasing the risk of further bleeding, the way anticoagulants inhibit the activation of neutrophils, a type of white blood cell that often acts as the first responders of the inflammatory system, offers a balance between antithrombotic benefits and hemorrhagic side effects, enabling healthcare providers to prevent thrombosis.
- Sector
- Healthcare
- HQ
- Gosselies, Belgium
- Founded
- 2010
- Employees
- 8
- Website
- bioxodes.com/
- Ownership
- Privately Held (backing)
Bioxodes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bioxodes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bioxodes in its N-PORT filings yet. We sweep new filings monthly.